Solid underlying financial performance and well-positioned for continued growthParis, France and Camberley, UK – 27 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the half year ended 30 June 2021. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-H1-results-final-.pdf
Visit PageNews and Events
Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
Paris, France and Camberley, UK – 16 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the proposed accounting treatment of the ongoing DHSC dispute on its unaudited H1 2021 interim results for the six months ended 30 June 2021. The interim results are expected to be announced
Visit PageProposition de traitement comptable du litige en cours avec le DHSC sur les résultats du premier semestre 2021
Paris, France et Camberley, UK – 16 septembre 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), un spécialiste international du diagnostic clinique, annonce le traitement comptable proposé du litige en cours avec le DHSC sur ses résultats non audités du premier semestre 2021, clos le 30 juin 2021. Les résultats du premier semestre 2021 devraient
Visit Page